David O’Connell, director of scientific and technical affairs, PCI Pharma explores the rise of ultra-high potency APIs and the limits of traditional HPAPI definitions.
PCI
The rise of ultra-high potency APIs
David O’Connell, director of scientific and technical affairs, PCI Pharma explores the rise of ultra-high potency APIs and the limits of traditional HPAPI definitions.
Published:
|
4 min read
Last updated:
Sign up to our newsletter
The week's biggest stories from this industry, direct to your inbox.